In one study, treatment of BRAF-inhibitor (BRAFi)-resistant melanoma cells with a miR-1246 mimic demonstrated downregulation of p-ERK and reduced vemurafenib antiproliferative activity [65]. Here, MAPK1 is linked to melanoma.